Table 4.
ARV regimens received by 3 or more of the 731 vertically infected subjects at enrolment
| ARV Regimena | N (%) |
|---|---|
| ZDV + ddI | 75 (10.3) |
| d4T + 3TC + NFV | 49 (6.7) |
| ZDV + ddI + NFV | 43 (5.9) |
| d4T + 3TC + RTV | 35 (4.8) |
| ZDV + 3TC + NFV | 33 (4.5) |
| d4T + ddI + NFV | 30 (4.1) |
| d4T + ddI + EFV + NFV | 25 (3.4) |
| ZDV + 3TC + NVP | 24 (3.3) |
| ZDV + 3TC | 23 (3.1) |
| d4T + ddI + RTV + SQV | 22 (3.0) |
| ZDV + 3TC + LPV/RTV | 18 (2.5) |
| d4T + ddI + EFV | 16 (2.2) |
| ZDV + ddI + EFV | 15 (2.1) |
| ZDV + 3TC + RTV | 15 (2.1) |
| d4T + ddI + LPV/RTV | 14 (1.9) |
| ZDV + 3TC + EFV | 13 (1.8) |
| ZDV + ABC + 3TC | 13 (1.8) |
| d4T + ddI + RTV | 12 (1.6) |
| d4T + 3TC + LPV/RTV | 12 (1.6) |
| d4T + 3TC + EFV | 12 (1.6) |
| ZDV + ddI + RTV | 11 (1.5) |
| ZDV + ddI + LPV/RTV | 9 (1.2) |
| d4T + 3TC + EFV + NFV | 7 (1.0) |
| d4T + ddI + NVP | 7 (1.0) |
| d4T + 3TC + NVP | 7 (1.0) |
| ZDV + ddI + NVP | 6 (0.8) |
| ZDV | 5 (0.7) |
| d4T + ddI | 4 (0.5) |
| d4T + ddI + EFV + LPV/RTV | 3 (0.4) |
| d4T + 3TC + NVP + NFV | 3 (0.4) |
| ddI + 3TC + EFV + NFV | 3 (0.4) |
| d4T + ddI + ABC | 3 (0.4) |
| d4T + 3TC | 3 (0.4) |
| Others | 43 (5.9) |
| No ARVs | 118 (16.1) |
aKey to ARV drug names: ZDV, zidovudine; ddI, didanosine; d4t, stavudine; 3TC, lamivudine; NFV, nelfinavir; RTV, ritonavir; EFV, efavirenz; NVP, nevirapine; SQV, saquinavir; ABC, abacavir; LPV, lopinavir.